Various Radiopharmaceuticals

The Department of the Army Medical Command has published a Special Notice regarding a sole source procurement for various radiopharmaceuticals. The Medical Readiness Contracting Office-West intends to award a Firm Fixed-Price call order to Sun Pharmaceuticals for FDA-approved radiopharmaceuticals including Sulfur Colloid, Pyrophosphate, Mebrofenin, MDP, and Mertiatide. This procurement is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees. The contract period will run from October 1, 2025 through September 30, 2026, with an anticipated award date of September 15, 2025. The solicitation is being processed under 10 United States Code 3204(a)(1) as a non-competitive procurement.

The primary purpose of this Special Notice is to announce the government's determination that only one source is reasonably available for these specialized radiopharmaceuticals, justifying the sole source award to Sun Pharmaceuticals. The notice establishes a deadline of July 25, 2025 for any responses, though it explicitly states that no capability briefings or telephonic inquiries will be honored. Contractors are advised that any information provided will not be used in subsequent solicitation requirements, effectively limiting participation opportunities. The procurement focuses on securing essential medical radiopharmaceuticals for military medical facilities, emphasizing the specialized nature of these pharmaceutical preparations. The government has determined that competitive bidding is not feasible due to the limited availability of qualified sources capable of providing these specific FDA-approved radiopharmaceutical products.